Navigation Links
Leading Biotechnology Company Awards Phase III Cardiac Safety Study to iCardiac
Date:9/24/2009

iCardiac continues #1 market position in automated QT studies

Rochester, NY (PRWEB) September 24, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac core lab services and QT analysis, announced today that a leading biotechnology company has awarded iCardiac a multi-center international Phase III cardiac safety study. iCardiac will provide end-to-end study management, site logistics and scientific reporting, as well as advanced ECG analytics. The study will utilize iCardiac's Highly Automated QT(sm) to dramatically improve study precision.

"We are pleased that the industry continues the rapid adoption of iCardiac's automated QT methods, which have demonstrated superiority to traditional manual or semi-automated ECG evaluation," said Sasha Latypova, Executive Vice President. "With this contract award, iCardiac continues its clear scientific and market leadership for automated QT studies with a larger number of studies completed or contracted than other commercial ECG core laboratories."

In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the "gold standard" manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically-differentiated cardiac core lab providing the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies for Phase I through Phase IV studies, supported by expert scientific consultation, end-to-end project management, worldwide site and equipment logistics, 24/7 customer support and regulatory data submission. iCardiac's analysis services provide drug developers with more precise and cost-effective methods for ECG interval measurements, including Highly Automated QT, which is the market leading solution for automated evaluation of QT intervals for regulatory submissions. In addition, iCardiac provides Beyond QT(sm), a suite of advanced ECG-based cardiac safety markers that have been accepted and used as a secondary end-point in regulatory approvals, and which delivers a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/number_one/automated_qt/prweb2930604.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
3. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
4. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
5. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
6. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
7. K-State Research Leading to Software to Help Nations Cattle Producers Identify Biosecurity Risks, Evaluate Impact of Cow-Calf Diseases Online
8. Leading Biotechnology Company Grows with StayinFront CRM
9. Leading Pharmaceutical Communication Executives Gather for the 1st Annual Pharmaceutical Public Relations Symposium
10. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
11. 2007 Massachusetts Biotechnology Council MASS Opportunities Investment Conference Showcases Leading Growth Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Parent Project Muscular Dystrophy ... end Duchenne muscular dystrophy (Duchenne) , today announced ... Jersey Institute of Technology (NJIT) and Talem Technologies (Talem) ... robotic technology to assist people living with Duchenne. ... technology – an embedded computer, software, a force sensor ...
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which creates medical ... submitted a 510(k) to the FDA, requesting clearance of the MyoCycle Home and ... (FES) technology. , The submission marks a major milestone for the technology ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Thirty-six startup ... tax credits by the Pennsylvania Department of Community and Economic Development in 2016 as ... are located in the University City Keystone Innovation Zone and represent the highest number ...
(Date:1/18/2017)... -- Market Research Future published a half-cooked research report on Global Cancer ... a CAGR of 12% during the period 2016 to 2022. ... ... division without any control. These abnormal cells have the ability to ... can spread to other parts of the body through the blood ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/8/2016)... , Dec. 8, 2016  Singulex, Inc., the ... Counting technology, entered into a license and supply agreement ... science. The agreement provides Singulex access to Thermo Scientific ... Europe is used to diagnose systemic bacterial ... States to aid in assessing the risk ...
(Date:12/7/2016)...   Avanade is helping Williams Martini Racing, ... history, exploit biometric data in order to critically analyse ... competitive edge against their rivals after their impressive, record-breaking ... has worked with Williams during the 2016 season to ... rate, breathing rate, temperature and peak acceleration) for key ...
Breaking Biology News(10 mins):